Literature DB >> 2112245

Long term treatment of myasthenia gravis with azathioprine.

V Fonseca1, C W Havard.   

Abstract

Twenty-seven patients with myasthenia gravis have been treated with azathioprine in conjunction with pyridostigmine and prednisolone for a total of 138 patient years. Side effects necessitated discontinuation of treatment in only four patients. Treatment with azathioprine was associated with marked clinical improvement in all the remaining 23 patients, resulting in reduction in the dose of pyridostigmine and prednisolone. The number of hospital admissions as well as the number of episodes of respiratory failure were markedly reduced.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112245      PMCID: PMC2429542          DOI: 10.1136/pgmj.66.772.102

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  15 in total

1.  The treatment of severe myasthenia gravis with immunosuppressive agents.

Authors:  H G Mertens; F Balzereit; M Leipert
Journal:  Eur Neurol       Date:  1969       Impact factor: 1.710

2.  Effect of immunosuppressive drugs (azathioprine).

Authors:  H G Mertens; G Hertel; P Reuther; K Ricker
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

3.  Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients.

Authors:  R M Pascuzzi; H B Coslett; T R Johns
Journal:  Ann Neurol       Date:  1984-03       Impact factor: 10.422

4.  Controversies about the treatment of myasthenia gravis.

Authors:  L P Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

5.  Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.

Authors:  J M Lindstrom; M E Seybold; V A Lennon; S Whittingham; D D Duane
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

6.  Intrahepatic cholestasis due to azathioprine.

Authors:  M Sparberg; N Simon; F del Greco
Journal:  Gastroenterology       Date:  1969-10       Impact factor: 22.682

7.  The long term experience of thymectomy for myasthenia gravis.

Authors:  G K Scadding; C W Havard; M J Lange; I Domb
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-05       Impact factor: 10.154

8.  Portal hypertension secondary to azathioprine in myasthenia gravis.

Authors:  V Fonseca; C W Havard
Journal:  Postgrad Med J       Date:  1988-12       Impact factor: 2.401

9.  Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange.

Authors:  J Newsom-Davis; A J Pinching; A Vincent; S G Wilson
Journal:  Neurology       Date:  1978-03       Impact factor: 9.910

10.  Diaphragmatic myasthenia in mother and child.

Authors:  A K Mier; C W Havard
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

View more
  5 in total

Review 1.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 2.  The natural course of myasthenia gravis.

Authors:  V Fonseca; C W Havard
Journal:  BMJ       Date:  1990-06-02

Review 3.  Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.

Authors:  Deepak Menon; Vera Bril
Journal:  Drugs       Date:  2022-05-31       Impact factor: 11.431

4.  A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

Review 5.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.